LXRX Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences

Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences

THE WOODLANDS, Texas, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at Citi's Biopharma Back to School Conference on Wednesday, September 3 at 1:45 p.m. ET and at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8 at 3:00 p.m. ET.

The live events and replays of the presentations can be accessed via the Events page of the Company’s website at .

About Lexicon Pharmaceuticals 

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon has advanced multiple medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, obesity, cardiology, diabetes and other indications. For additional information, please visit . 

For Investor and Media Inquiries

Lisa DeFrancesco

Lexicon Pharmaceuticals, Inc. 

 



EN
27/08/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lexicon Pharmaceuticals Inc.

 PRESS RELEASE

Lexicon to Present Data on Effect of Kidney Function on the Long-term ...

Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes Post hoc data analysis concluded that sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, improved glycemic control after one year in patients with normal and mildly reduced kidney function THE WOODLANDS, Texas, March 11, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: LXRX) today announced that results of a post hoc analysis of clinical data evaluating the impact of kidney function...

 PRESS RELEASE

Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results ...

Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM  Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase 3 readiness and supports ongoing partnership discussions Strengthened financial position with more than $100 million in additional cash from capital raise and Novo Nordisk milestone payment Conference call and webcast at 8:30 am ET   THE WOODLANDS, Texas, March 05, 2026 (GLOBE NEWSWIRE) -- (Na...

 PRESS RELEASE

Lexicon Pharmaceuticals to Participate in Three Upcoming March Investo...

Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences THE WOODLANDS, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in an upcoming fireside chat at the 2026 Leerink Partners Global Healthcare Conference in Miami on Wednesday, March 11, at 10:00 a.m. Lexicon will also be participating in 1x1 investor meetings at the 2026 Jefferies Biotech on the Beach Summit, March 10–11, and at the Barclays 28th Global Healthcare Conference, March 10-12. A live recording and re...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: February 28, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Result...

Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026 THE WOODLANDS, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter 2025 financial results on Thursday, March 5, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company’s website ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch